Comparison of gliclazide treatment with diet therapy on acute phase protein levels in patients with type 2 diabetes

Turkish Journal of Medical Sciences

Volumn 39, Issue 1, 2009, Pages 73-76

  Memişoǧullari, Ramazan ^a   Akçay, Fatih ^b   Coşkun, Abdurrahman ^a   Korkmaz, Uǧur ^a  

^a DUZCE UNIVERSITY   (Turkey)

^b ATATURK UNIVERSITY   (Turkey)

Author keywords

Acute phase proteins; Diabetes mellitus; Gliclazide; Inflammation

Indexed keywords

ACUTE PHASE PROTEINS; ACUTE-PHASE REACTANTS; ANTIDIABETIC; ANTITRYPSIN; C-REACTIVE PROTEINS; CHRONIC INFLAMMATIONS; CONTROL GROUPS; DIABETES MELLITUS; GLICLAZIDE; HEALTHY SUBJECTS; INFLAMMATION; MACROGLOBULIN; SERUM LEVELS; TYPE-2 DIABETES;

ACIDS; BODY FLUIDS; ECOLOGY; GLUCOSE; GLYCOPROTEINS; NUTRITION; PATHOLOGY; SUGAR (SUCROSE);

PROTEINS;

ACUTE PHASE PROTEIN; ALBUMIN; ALPHA 1 ANTITRYPSIN; ALPHA 2 MACROGLOBULIN; BETANORM; C REACTIVE PROTEIN; GLICLAZIDE; GLUCOSE; HAPTOGLOBIN; HEMOGLOBIN A1C; OROSOMUCOID; PREALBUMIN; TRANSFERRIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

EID: 63449133967     PISSN: 13000144     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Mernisogullari R, Bakan E. Levels of ceruloplasmin, transferrin, and lipid peroxidation in the serum of patients with Type 2 diabetes mellitus. J Diabetes Complications 2004; 18: 193-7.
2. Mc Millan DE. Increased levels of acute-phase serum proteins in diabetes. Metabolism 1989; 38: 1042-6.
3. Schmidt Ml, Duncan BB, Sharrett AR, Lindberg G, Savage PJ, Offenbacher S et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet 1999; 353: 1649-52.
4. Ceriello A. Effects of gliclazide beyond metabolic control. Metabolism 2006; 55 (Suppl 1): S10-S15.
5. Miva S, Watada H, Ohmura C, Tanaka Y, Kawamori R. Efficacy and safety of once daily gliclazide (20 mg/day) compared with nateglinide. Endocr J 2004; 51: 393-8.
6. Räkel A, Renier G, Roussin A, Buithieu J, Mamputu JC, Serri O. Beneficial effects of gliclazide modified release compared with glibenclamide on endothelial activation and low-grade inflammation in patients with type 2 diabetes. Diabetes Obes Metab 2007: 9(1): 1279.
7. Khanolkar MP, Morris RH, Thomas AW, Bolusani H, Roberts AW, Geen J et al. Rosiglitazone produces a greater reduction in circulating platelet activity compared with gliclazide in patients with type 2 diabetes mellitus - an effect probably mediated by direct platelet PPARgamma activation. Atherosclerosis 2008; 197(2): 718-24.
8. Gomes MB, Nogueira VG. Acute-phase proteins and microalbuminuria among patients with type 2 diabetes. Diabetes Res Clin Pract 2004; 66: 31-9.
9. Fournier T, Medjoubi-N N, Porquet D. Alpha-1 -acid glycoprotein. Biochim Biophys Acta 2000; 1482: 157-71.
10. Phadke M, Billimoria FR, Ninjoor V. Non enzymatic glycosylation of alpha-1-proteinase inhibitor of human plasma. JPGM 1998; 44: 29-34.
11. Tseng CF, Lin CC, Huang HY, Liu HC, Mao SJT. Antioxidant role of human haptoglobin. Proteomics 2004; 4; 2221-8.
12. Ebeling P, Teppo AM, Koistinen HA, Viikari J, Rönnemaa T, Nisson M et al. Troglitazone reduces hyperglycaemia and selectively acute-phase serum proteins in patients with Type II diabetes. Diabetologia 1999; 42: 1433-8.
13. Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997; 40: 1286-92.
14. Rema M, Mohan V, Snehalatha C. Acute phase serum proteins in diabetic retinopathy. Indian J Ophthalmol 1996; 44: 83-5.